Category: Today’s Highlights
Xoma: Why this Firm's Upcoming Conference Call Is Very Important
Xoma’s (XOMA) webcast and conference call scheduled for September 15, 2016 , at 1:30 p.m. PDT (4:30 p.m. EDT) is important and should be interesting to the firm’s shareholders. The conference call will provide an update on what’s going on...
Read More
September 9, 2016
0
Reasons for Vertex's & Illumina's Outperformance
Synopsis Most of the Prohost picked stocks gained momentum and closed higher at the end of the week. Some rallied because that’s what they were supposed to do after the quarterly financial when most biotech stocks are subjected to selloffs,...
Read More
August 7, 2017
0
Has the Time Come for Array Biopharma to Start Rallying?
At the European Society of Cardiology Congress 2016 in Rome, Italy, Array Biopharma (ARRY) presented good results from a Phase 2 study of its drug ARRY-797 - an oral, selective p38 mitogen-activated protein kinase inhibitor for patients with a rare...
Read More
August 31, 2016
0
About Nymox Pharmaceutical Drug Fexapotide for the Prevention of Prostate Cancer
Benign Prostate Hypertrophy (BPH) Is Fexapotide the Safest and Effective Prostate Cancer Preventative? That’s what Nymox Pharmaceutical (NYMX) announced in its recent press release stating that results from from 7-year prospective placebo controlled double blind studies of treatment of 995...
Read More
August 25, 2016
0
Learning from Pfizer Acquisition. Regeneron to Fight Zika and More
Pfizer accepted to pay $14 billion in cash to acquire Medivation. It is important for investors to know what Pfizer is after with regard to this acquisition so that investors could sense the current deep-pocketed biopharmaceutical firms’ preferences in selecting...
Read More
August 23, 2016
0
Stocks' Declines That Offer Real Opportunities for Accumulation at Bargain Prices
AFTER MANY OF THE PROHOST PICKED STOCKS NEARED REACHING THE PROHOST NEAR-TERM TARGETS, recently, external circumstances and exaggerated delaying news, some of our rallied stocks gave back some of their gains. Two reasons were behind the decline in some precious...
Read More
August 15, 2017
0
Why Sangamo Rallied
About Our New Section On Sunday, August 20, 2017 we will post our first “The Week in Review” article. This current week has carried bad news, political hypocrisy and a catastrophic terrorist attack on the people of Spain. The week...
Read More
August 18, 2017
0
Why Portola Is Still Favorite
What’s Going on the Morning of Thursday, August 18, 2016? PORTOLA Portola Pharmaceuticals (PTLA) announced the receipt of a Complete Response Letter (CRL) from the FDA regarding its Biologics License Application (BLA) for AndexXa™ (andexanet alfa). An FDA-designated Breakthrough Therapy,...
Read More
August 18, 2016
0
Radius Health: A New Osteoporosis Drug That Might Prevent Bone Fracture?
JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women with Osteoporosis The Company is Radius Health (RDUS) and the new expected to be soon approved drug, abaloparatide, is an investigational therapy for the potential treatment of women with...
Read More
August 18, 2016
0
Gilead and Genmab Agreement. A Quick Look at Moderna
GILEAD & GENMAB To Access Genmab’s (GEN) bispecific antibody technology, Gilead (GILD) signed a new agreement with Genmab. The King of HIV treatment objective is to use its exclusive license from Genmab to produce an HIV bispecific monoclonal antibody therapeutic....
Read More
August 15, 2016
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)